International Archives

Blog

What NRDL 2025 Outcomes Mean for Drug Pricing and Market Access in China

September 17, 2026

China's reimbursement environment changed with the introduction of the NRDL value rating framework in 2023 and the Commercial Insurance Innovative Drug List (CIIDL) in 2025. NRDL 2025 outcomes show that payers continue rewarding breakthrough therapies, comparative evidence, and treatments for unmet...

Market Access Trends 2026

How MFN and Direct-to-Consumer Models Are Rewiring US Market Access

March 23, 2026

Globally, 2025 marked a shift from debating drug pricing policy to implementing it. Pricing pressure intensified, evidence expectations rose, and long-standing access models began to change amid political and fiscal realities. In Trinity’s webinar “Around the World in Market Access 2026:...

Blog

NRDL 2024: Rare Diseases Deep Dive

July 1, 2025

China’s pharmaceutical landscape is not only vast in scale but also rapidly evolving with an emphasis on balancing access with affordability. This year’s NRDL update stands out. The introduction of the value rating system continues to raise the bar for clinical...

Blog

Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know

June 13, 2025

March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences,...

Blog

Pricing and Access in Germany: Innovation and Strong Evidence Rewarded

June 9, 2025

Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated...

Blog

5 Key Trends in Global Market Access

December 12, 2024

Key impacts on the market access and payer environment are beginning to unfold from policies enacted in 2023 and new policies enacted in 2024. To gather insights into the latest trends, Trinity Life Sciences conducted interviews with key stakeholders across various...

Blog

Rise with the Waves: UK – Now and Beyond – Four Policy Trends That May Shape Pharma’s Future

May 23, 2024

Executive Summary The global payer landscape is rapidly evolving and is expected to continuously impact manufacturers’ decisions about new launches, portfolio management, trial design and importantly, pricing and market access strategy. In the UK, several policy reforms have been introduced which...

Blog

Japan Pricing Policy Reform 2024

May 17, 2024

Executive Summary The Central Social Insurance Medical Council, the key Japanese reimbursement policy panel known as Chuikyo, introduced the 2024 drug pricing reform in April 2024. Some key features of the reform plan include: The reform outlines a suite of measures aimed at...

Blog

Rise with the Waves: France – Accelerating Pricing and Market Access: Two Policies Shaping Pharma’s Future

April 22, 2024

Executive Summary The latest publication of new reimbursement regulations in the French Social Security Financing Act (PLFSS 2024), coupled with the recent approval of HEMGENIX® through the direct access scheme in France this past December, underline continued efforts in France to...

Blog

Rise with the Waves: Italy – AIFA Restructuring and Budget Reforms – Stepping into a New (Uncertain) Future?

March 20, 2024

Executive Summary The Italian Medicines Agency (AIFA) underwent transformative changes on January 30, 2024, following a much-anticipated reorganization. AIFA’s restructuring has already faced challenges, with the recent resignation of the newly created Scientific and Economic Commission’s (CSE) chairman followed by the...

Blog

Rise with the Waves: Germany – A Tale of Two High Impact Policies Shaping Pharma’s Future

February 26, 2024

Executive Summary Multiple cost-containment reforms, such as the introduction of a 20% rebate on brand-brand combinations and a temporary increase in the mandatory rebate on drugs to 12%, were implemented under Germany’s ‘Financial Stabilization of Statutory Health Insurance System’ Act (GKV-Finanzstabilisierungsgesetz)...

Blog

Key Takeaways and Learnings from ISPOR Europe 2023

December 7, 2023

Trinity Life Sciences recently attended the ISPOR Europe 2023 conference in Copenhagen, Denmark. The main theme of the conference was “HEOR at the Nexus of Policy and Science,” and the event featured unique discussions and workshops across different stakeholders from both...